Corneal TransplantationNCT03105466
Prospective Study of Deep Anterior Lamellar Keratoplasty Using Acellular Porcine Cornea
A study testing Deep anterior lamellar keratoplasty, Acellular Porcine Cornea and Tacrolimus eye drops in people with Corneal Transplantation, run by Zhongshan Ophthalmic Center, Sun Yat-sen University at 1 site in China.
Trial summary
The performance of keratoplasty is hampered by the limited availability of donor cornea in many countries, especially in Asia. For this reason, attempts have been made to fabricate artificial substitutes for natural human cornea. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Corneal Transplantation
- What is being tested?
- Deep anterior lamellar keratoplasty, Acellular Porcine Cornea and Tacrolimus eye drops
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteChina
- Study dates
- Feb 2016to Feb 2020
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- corneal diseases not involving the endothelial layer
Who cannot join
- corneal diseases involving the endothelial layer
- allergic to pig tissue
- do not accept xenotransplantation
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Zhongshan Ophthalmic Center, Sun Yat-Sen University
Guangzhou, Guangdong, 510080
Saiqun Li, M.D., Ph.D., 86-013642710612, 123213197@qq.com
Jin Yuan, M.D., Ph.D.
About this study
The performance of keratoplasty is hampered by the limited availability of donor cornea in many countries, especially in Asia. For this reason, attempts have been made to fabricate artificial substitutes for natural human cornea. So far, all polymeric biomaterials, such as collagen configurations and plastic compression, could mimic the functional optically transparent but failed to replicate the complicate three-dimension microstructure of natural cornea. Therefore, despite some favorable results yielded by polymeric biomaterials, they cannot be suited for long-term use. To overcome these disadvantages, in recent years, porcine cornea appeared specifically attractive for xenotransplantation, because of its accessibility and similarities to natural human cornea. However, xenotransplantation using fresh porcine cornea can occurs hyperacute immune rejection, resulting in graft failure. Such transplant rejection can be substantially lessened by using acellular porcine cornea (APC), which preserves the constructure of natural cornea, whilst having well biocompatibility and low antigenicity. These properties feature APC particularly suitable for high-risk keratoplasty, such as corneal grafting in infectious keratitis.
Use of APC in LK has been shown promise in many preclinical animal studies and initially in human clinic trail. However, to optimize APC biological and biomechanical properties, the strategies for its preparation has evolved extensively over recent years, like various decellularization approaches (e.g. detergents, enzymes, human sera, hypertonic solutions and et al) and additional procedures (e.g. collagen re-crosslinking and repeated frozen-dry). Therefore, in the current study, the investigators analyzed the early surgical outcomes of deep anterior lamellar keratoplasty (DALK) using the APC that was very recently approved by the National Institutes for Food and Drug Control (NIFDC) of China for clinic practice, for management of infective keratitis, including fungal, viral and acanthamoeba keratitis. Here major concern of this study was to clarify the behavior of APC after implantation in participants.
- Conditions
- Corneal Transplantation
- Being tested
- Deep anterior lamellar keratoplasty, Acellular Porcine Cornea, Tacrolimus eye drops, Tobradex eyedrops
- Keywords
- Corneal Transplantation, Xenotransplantation, Bioegineered cornea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Deep anterior lamellar keratoplastyProcedure or surgery
Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
Acellular Porcine CorneaDevice
Tacrolimus eye dropsDrug
Tobradex eyedropsDrug
| Study group | Role | What they receive |
|---|---|---|
| Acellular porcine cornea group | Experimental | Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea Receives: Procedure: Deep anterior lamellar keratoplasty; Device: Acellular Porcine Cornea; Drug: Tacrolimus eye drops; Drug: Tobradex eyedrops |
What is being measured
The primary outcome is the main question the study is designed to answer.
the changes of Best corrected visual acuity
Measured: Before surgery, 1-week, 1-month, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year after surgery
Secondary outcomes (5)
the changes of visual contrast sensitivity
Measured: Before surgery, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year after surgery
the changes in the transparency of graft
using Slit lamp microscopic evaluation
Measured: 1-week, 1-month, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year after surgery
The changes in corneal thickness depth
using anterior segmental OCT
Measured: 1-week, 1-month, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year after surgery
The changes in corneal nerve regeneration
using Confocal microscopy
Measured: 1-month, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year after surgery
The changes of depression and anxiety status
Using Self-Rating Depression Scale (SDS) and Self-Rating Anxiaty Scale (SAS)
Measured: Before surgery, 1-month, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2017
- Study startFeb 2016
- Primary completionFeb 2020 (estimated)
- Study completionFeb 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Corneal TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jin Yuan, Zhongshan Ophthalmic Center, Sun Yat-sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03105466
- Sponsor's protocol ID
- 2016021
- Status last verified
- Apr 2017
- First submitted
- 31 Aug 2016
- Last updated
- 10 Apr 2017
- Results posted
- No
Publications
Li S, Li M, Gu L, Peng L, Deng Y, Zhong J, Wang B, Wang Q, Xiao Y, Yuan J. Risk factors influencing survival of acellular porcine corneal stroma in infectious keratitis: a prospective clinical study. J Transl Med. 2019 Dec 30;17(1):434. doi: 10.1186/s12967-019-02192-z.
PubMed 31900186